1 Value Stock to Research Further and 2 We Ignore

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here is one value stock with strong fundamentals and two with little support.

Forward P/S Ratio: 1.4x

Powering billions of daily ad impressions across the open internet, PubMatic (NASDAQ:PUBM) operates a technology platform that helps publishers maximize revenue from their digital advertising inventory while giving advertisers more control and transparency.

Why Are We Out on PUBM?

Platform has low switching costs as its net revenue retention rate of 96% demonstrates high turnover

Extended payback periods on sales investments suggest the company’s platform isn’t resonating enough to drive efficient sales conversions

Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 7.4 percentage points

PubMatic’s stock price of $8.20 implies a valuation ratio of 1.4x forward price-to-sales. To fully understand why you should be careful with PUBM, check out our full research report (it’s free).

Forward P/E Ratio: 7.6x

Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.

Why Are We Wary of JAZZ?

Annual revenue growth of 5.5% over the last two years was below our standards for the healthcare sector

Efficiency has decreased over the last five years as its adjusted operating margin fell by 26.8 percentage points

Earnings per share fell by 8% annually over the last five years while its revenue grew, partly because it diluted shareholders

At $181.45 per share, Jazz Pharmaceuticals trades at 7.6x forward P/E. If you’re considering JAZZ for your portfolio, see our FREE research report to learn more.

Forward P/E Ratio: 9.5x

Originally spun off from General Electric in 2005 to provide business process services, Genpact (NYSE:G) is a global professional services firm that helps businesses transform their operations through digital technology, AI, and data analytics solutions.

Why Are We Positive On G?

Share repurchases over the last five years enabled its annual earnings per share growth of 11.5% to outpace its revenue gains

G is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders

Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures, and its rising returns show it’s making even more lucrative bets

Genpact is trading at $38.34 per share, or 9.5x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.